Abstract:Objective To explore the feasibility and efficacy of an optimized antiplatelet therapy according to laboratory test after coronary stenting.Methods Between June 2006 and February 2007,a total of 305 patients who underwent coronary stenting in General Hospital of Shenyang Command were enrolled.Patients were randomly assigned to receive optimized(optimal group,n=154)or standard antiplatelet therapy(standard group,n=151).Clopidogrel resistance(CR)was defined as a less than 10% reduction of platelet aggregation at 24h after clopidogrel treatment.The antiplatelet regimen for standard group was dual antiplatelet therapy with aspirin and clopidogrel.In optimal group,CR patients received cilostazol for 6 months in addition to dual anitplatelet therapy,whereas non-CR patients received standard dual antiplatelet therapy.The primary endpoint of present study was the composite analysis of death,myocardial infarction(MI)or stroke.Secondary endpoint was the composite analysis of death,MI,stroke,revascularization or peripheral artery occlusion.Results There were 41 and 33 CR patients in optimal and standard group,respectively.Cilostazol in addition to dual antiplatelet therapy decreased significantly the PAR of CR patients in optimal group(77.5%±12.1% vs 64.5%±12.1%,P<0.001).At one-year follow-up,patients in optimal group were associated with a 37% reduction in the risk of cardiovascular events compared with those in standard group(5.8% vs 9.3%,P=0.257).The incidence of a composite of cardiac death,myocardial infarction,stroke,revascularization or occlusion of lower extremity artery was decreased in optimal group compared with those in standard group(9.7% vs 14.6%,P=0.197).No significant difference existed in incidence of stent thrombosis and hemorrhagic events between the two groups.CR patients in optimal group had a lower but not statistically significant incidence of primary cardiovascular and cerebral ischemic events(19.5% vs 36.4%,P=0.105).Conclusions Adjusting antiplatelet regimen according to PAR assay results might be effective in improving long-term outcomes for patients undergoing coronary stenting,especially for those diagnosed as CR.However,the effectiveness and safety need further confirmation by large-scale clinical trials.

Intervention effect for the serum platelet-activating factor level in patients after coronary artery stenting

Impacts of Atherosclerotic Plaque Composition and Platelet Aggregation on Serum Cardiactroponin T Elevation after Percutaneous Coronary Interventions

Effects of liposomal prostaglandin E1 on fibrinolytic system in peri-percutaneous coronary interventional in acute coronary syndrome

Serial Changes in Circulating Platelet Activation and Platelet Aggregation after Carotid Artery Stenting

Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity after Coronary Stent Implantation

To Compare the Curative Effect of the Antiplatelet Therapy Between Puerarin Injection and Xueshuantong Injection Among Patients with Unstable Angina After Percutaneous Coronary Stent Implantation

Changes of Platelet Activation Markers and Platelet Ultra-Microstructure in the Patients with Acute Myocardial Infarction

Changes of Plasma P-selectin、 Thrombomodulin、 Plasminogen Activator Inhibitor-1 of Coronary Artery Disease Patients Before and after PTCA

Clinical effect of postconditioning in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.

The Effects of Post Coronary Stenting Triple Antiplatelet Therapies on Platelet Functions

Temporal Changes in Circulating P-selectin, Plasminogen Activator Inhibitor-1, Magnesium, and Creatine Kinase after Percutaneous Coronary Intervention

Serial Changes of Circulating Platelet Activation Markers after Carotid Artery Stenting

Correlation between tissue factor pathway inhibitor and coronary artery diseases

[The Antiplatelet Effect of Clopidogrel is Not Attenuated by Statin Treatment in Patients with Acute Coronary Syndromes Undergone Coronary Stenting].

Effect of Different Doses of Cilostazol Intensive Antiplatelet Therapy on the Patients with High On-treatment Platelet Reactivity after Coronary Stent Implantation

Effects of Triple Antiplatelet Therapy on Patients Undergone Coronary Artery Stenting

Effect of high dose statin pretreatment for percutaneous coronary intervention patients with acute coronary syndrome

The interventional treatment of non-ST-segment elevation acute coronary syndromes

Effect of different duration of clopidogrel pretreatment on platelet activation in patients undergoing stenting

Optimal antiplatelet therapy after coronary stenting,a single-center randomized controlled pilot study

Influences of tirofiban hydrochloride on platelet aggregation rate,sCD40L level and prognosis in patients with non-ST-elevation acute coronary syndrome